Fort Myers, FL and Scottsdale, AZ (PRWEB) August 20, 2013
21st Century Oncology today announced it will more closely combine cancer research initiatives with Massachusetts General Hospital (MGH), the original and largest teaching affiliate of Harvard Medical School (HMS).
Currently, 21st Century Oncology, the largest U.S. radiation therapy provider, conducts cancer research alongside MGH within the framework of the Radiation Therapy Oncology Group (RTOG), a national cancer research organization funded by the National Cancer Institute (NCI) to increase the survival rates and improve the quality of life of patients diagnosed with cancer.
In February 2014, the NCI will implement a reorganized cooperative structure, combining three specialized oncology research bodies into one, all-encompassing clinical research collective. The National Surgical Adjuvant Breast and Bowel Project (NSABP), the RTOG, and the Gynecologic Oncology Group (GOG) will become NRG Oncology.
“We are pleased to continue this relationship with Massachusetts General Hospital under the NRG reorganization,” says Daniel Dosoretz, MD, FACR, FACRO, President, CEO and Co-Founder of 21st Century Oncology. “The research and clinical trials we conduct today will improve outcomes for patients with cancer moving forward.”
21st Century Oncology is conducting clinical research trials at sites across the country and assessing the effectiveness of various cancer treatments. “Physicians are currently evaluating advanced therapy in breast cancer, prostate cancer and bladder cancer and look forward to expanding to other sites including lung cancer,” says Steven Finkelstein, MD, National Director, 21st Century Oncology Translational Research Consortium.
“I am pleased as the Principal Investigator of the MGH/HMS, full membership within the RTOG, to be continuing our relationship with 21st Century Oncology to increase the participation for pa
Copyright©2012 Vocus, Inc.
All rights reserved